Literature DB >> 3814200

An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report.

O Førre, F Bjerkhoel, C F Salvesen, K J Berg, H E Rugstad, G Saelid, O J Mellbye, E Kåss.   

Abstract

Cyclosporine (10 mg/kg/day) and azathioprine (2.5-3 mg/kg/day) were compared for 26 weeks in an open, controlled, randomized study of 24 patients with rheumatoid arthritis. Each treatment group consisted of 12 patients. Those patients who took cyclosporine improved significantly in the 50-foot walk time, circumferences of proximal interphalangeal joints, Ritchie articular index, global assessment by investigator, and grip strength, when compared with baseline findings. In the azathioprine group, there was improvement only in grip strength.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3814200     DOI: 10.1002/art.1780300112

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

1.  Penetration of cyclosporin into synovial fluid in rheumatoid arthritis.

Authors:  A W van Rijthoven; B A Dijkmans; H S Goei Thè; M Boers; A Cats
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  New approaches to the treatment of rheumatoid arthritis.

Authors:  P A Miescher; Y P Huang; R H Zubler
Journal:  Springer Semin Immunopathol       Date:  1988

Review 3.  Cyclosporine and rheumatoid arthritis.

Authors:  O Førre; K Waalen; H E Rugstad; K J Berg; D Solbu; E Kåss
Journal:  Springer Semin Immunopathol       Date:  1988

4.  Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis.

Authors:  E Flescher; T L Bowlin; A Ballester; R Houk; N Talal
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

5.  The clinical and immunological effects of cyclosporin A on patients with rheumatoid arthritis.

Authors:  D M Chang; S F Chiao
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

6.  Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis.

Authors:  M Dougados; L Duchesne; H Awada; B Amor
Journal:  Ann Rheum Dis       Date:  1989-07       Impact factor: 19.103

Review 7.  New perspectives of secondary and tertiary therapy for rheumatoid arthritis.

Authors:  R F Willkens
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 8.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  Comparison of cyclosporin A and azathioprine in the treatment of rheumatoid arthritis--results of a double-blind multicentre study.

Authors:  K Krüger; M Schattenkirchner
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

Review 10.  Outcome measures for gait and ambulation in the spinal cord injury population.

Authors:  Amie B Jackson; Charles T Carnel; John F Ditunno; Mary Schmidt Read; Michael L Boninger; Mark R Schmeler; Steve R Williams; William H Donovan
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.